Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Up to a quarter of people in the UK with a diagnosis of dementia are prescribed an antipsychotic in any year. The potential risks of such treatment are becoming clearer, but the benefits remain uncertain. Concern about the frequency and quality of such prescribing was expressed in the National Dementia Strategy for England in 2009. Aims: To provide an estimate of the prevalence of antipsychotic use for dementia in secondary mental health services in the UK and to collect data relevant to quality improvement initiatives for such prescribing practice. Method: In the context of a UK quality improvement programme, relevant clinical audit data were collected for patients with dementia under the care of specialist older people's mental health services. Results: Fifty-four mental health National Health Service (NHS) trusts submitted data on 10 199 patients. Of those patients without comorbid psychotic illness, 1620 (16%) were prescribed an antipsychotic; the common clinical indications for such medication were agitation, psychotic symptoms, aggression and distress. Multivariable regression found younger age, care home or in-patient setting, vascular or Parkinson's disease dementia and greater severity of dementia to be all significantly associated with being prescribed antipsychotic medication. Of the 1001 (62%) patients prescribed treatment for more than 6 months, only three-quarters had a documented review of therapeutic response in the previous 6 months. Conclusions: The data reveal areas of relatively good current practice, including consideration of alternatives to antipsychotic medication and clear documentation of target symptoms. They also suggest areas for improvement, such as the frequency and quality of review of long-term medication. Strategies to reduce antipsychotic use should take account of the demographic and clinical variables predicting increased likelihood of antipsychotic prescription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“9,10 In the UK the National Institute for Health and Clinical Excellence (NICE) clinical guideline for the management of dementia, published in 2006, recommended that antipsychotic drugs should not be prescribed for patients whose non-cognitive symptoms were of mild to moderate severity because of…”
Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., Matthews, F. E., Smithard, D., Coulton, S., Katona, C., Boustani, M. A., & Brayne, C. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03491.x · Cited by 655 · cited 1×
“28 Further, this activity would be likely to negate the effects of the cholinesterase inhibitors in the 25% of patients prescribed both an antipsychotic and a cholinesterase inhibitor.”
Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“25,26 In contrast, there is no evidence supporting the efficacy of valproate but some indicating potential harm.”
Self-citationRisk of Mortality Among Individual Antipsychotics in Patients With Dementia
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., Cunningham, F., Schneider, L. S., & Blow, F. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030347 · Cited by 384
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Antidepressants for agitation and psychosis in dementia
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008191.pub2 · Cited by 304 · cited 1×
“25,26 In contrast, there is no evidence supporting the efficacy of valproate but some indicating potential harm.”
Cited by
Adverse drug reactions in special populations – the elderly
Davies, E. A., & O'Mahony, M. S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12596 · Cited by 604
Selbæk, G., Engedal, K., & Bergh, S. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.09.027 · Cited by 270
Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses
Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316658463 · Cited by 267
Ballard, C., Orrell, M., YongZhong, S., Moniz-Cook, E., Stafford, J., Whittaker, R., Woods, B., Corbett, A., Garrod, L., Khan, Z., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010130 · Cited by 142
Antipsychotic Use in Dementia: Is There a Problem and Are There Solutions?
Kirkham, J., Sherman, C., Velkers, C., Maxwell, C., Gill, S., Rochon, P., & Seitz, D. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716673321 · Cited by 113
Metadata
- Authors
- Barnes, T. R. E., Banerjee, S., Collins, N., Treloar, A., McIntyre, S. M., & Paton, C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2012-09
- Volume
- 201
- Issue
- 3
- Pages
- 221-226
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2120394330
- Cited by
- 89
- References
- 8
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. https://app.cochat.ai/papers/10.1192/bjp.bp.111.107631
- The paper
- Barnes, T. R. E., Banerjee, S., Collins, N., Treloar, A., McIntyre, S. M., & Paton, C. (2012). Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.111.107631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.